Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1956 1
1957 1
1961 1
1965 1
1966 2
1971 1
1973 1
1974 1
1975 1
1976 1
1977 1
1978 1
1980 2
1983 3
1984 6
1985 4
1986 5
1987 2
1988 2
1989 1
1990 2
1991 2
1992 1
1993 2
1994 2
1995 2
1996 2
1998 4
1999 3
2000 1
2001 4
2002 4
2003 5
2004 7
2005 4
2006 11
2007 7
2008 3
2009 8
2010 7
2011 3
2012 4
2013 1
2014 8
2015 6
2016 1
2017 3
2018 2
2019 7
2020 7
2021 7
2022 9
2023 9
2024 12
2025 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

206 results

Results by year

Filters applied: . Clear all
Page 1
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Novák Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanker LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ, Tian M, He Z, Stevens S, Zografos E, Coleman RL, Powell MA; RUBY Investigators. Mirza MR, et al. N Engl J Med. 2023 Jun 8;388(23):2145-2158. doi: 10.1056/NEJMoa2216334. Epub 2023 Mar 27. N Engl J Med. 2023. PMID: 36972026 Clinical Trial.
Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
Powell MA, Cibula D, O'Malley DM, Boere I, Shahin MS, Savarese A, Chase DM, Gilbert L, Black D, Herrstedt J, Sharma S, Kommoss S, Gold MA, Thijs AM, Ring K, Bolling MF, Buscema J, Gill SE, Nowicki P, Nevadunsky N, Callahan M, Willmott L, McCourt C, Billingsley C, Ghamande SA, He Z, Balas MM, Stevens S, Fleming E, Mirza MR. Powell MA, et al. Among authors: nowicki p. Gynecol Oncol. 2025 Jan;192:40-49. doi: 10.1016/j.ygyno.2024.10.022. Epub 2024 Nov 12. Gynecol Oncol. 2025. PMID: 39531903 Free article. Clinical Trial.
Research on Green Adsorbents.
Wiśniewska M, Nowicki P. Wiśniewska M, et al. Among authors: nowicki p. Molecules. 2024 Apr 19;29(8):1855. doi: 10.3390/molecules29081855. Molecules. 2024. PMID: 38675675 Free PMC article.
What Is New in Pediatric Bone Health.
Beck JJ, Mahan ST, Nowicki P, Schreiber VM, Minkowitz B. Beck JJ, et al. Among authors: nowicki p. J Pediatr Orthop. 2021 Sep 1;41(8):e594-e599. doi: 10.1097/BPO.0000000000001896. J Pediatr Orthop. 2021. PMID: 34231540 Review.
Sonography of pathological changes in the hand.
Dębek A, Czyrny Z, Nowicki P. Dębek A, et al. Among authors: nowicki p. J Ultrason. 2014 Mar;14(56):74-88. doi: 10.15557/JoU.2014.0007. Epub 2014 Mar 30. J Ultrason. 2014. PMID: 26675521 Free PMC article. Review.
Universities should lead on the plant-based dietary transition.
Krattenmacher J, Casal P, Dutkiewicz J, Huchard E, Sanders E, Treich N, Wadiwel D, Williams A, Bègue L, Cardilini APA, Dhont K, Dugnoille J, Espinosa R, Gagliano M, Lairon D, Maheta M, Mendez L, Nowicki P, Quinn TP, Razum O, Ripple WJ, Rothgerber H, Twine R. Krattenmacher J, et al. Among authors: nowicki p. Lancet Planet Health. 2023 May;7(5):e354-e355. doi: 10.1016/S2542-5196(23)00082-7. Lancet Planet Health. 2023. PMID: 37164509 Free article. No abstract available.
206 results